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This single center prospective study is being conducted to evaluate the safety of the cryoablation for 
patients with pathologically diagnosed painful bone and soft tissue tumors.  Enrollment of 10 patients 
is planned over the 3-year recruitment period.  Patients have related local pain after receiving medica-
tions or external radiation therapies will be included in this study.  Cryoablation will be percutaneously 
performed under imaging guidance,  and a temperature sensor will be used during treatment as neces-
sary.  The primary endpoint is prevalence of severe adverse events within 4 weeks after therapy.  The 
secondary endpoint is eﬀectiveness 4 weeks after the procedure.
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P atients with painful bone and soft tissue tumors,  including both benign and malignant tumors,  are 
usually treated with medication and/or external radia-
tion therapy to control or alleviate their pain.  
However,  some patients have uncontrollable pain or 
recurrence of pain after these treatments.  The wors-
ening of the quality of life (QOL) caused by painful 
bone and soft tissue tumors such as bone metastases is 
a serious social problem.  Although surgical resection 
of the painful tumor is sometimes performed for these 
patients,  tumor location,  tumor size,  patient comor-
bidities,  and general conditions can limit those that 
can undergo surgery.  Additionally,  surgical interven-
tions can potentially lead to post-surgical dysfunc-
tions.
　 According to a meta-analyses examining the clinical 
outcomes of the external radiation therapy for patients 
with metastatic bone pain,  complete or partial pain 
relief is obtained in 23–34  and 59–73  of patients,  
respectively ［1–3］.  In other words,  metastatic bone 
pain in 30–40  of patients cannot be relieved using 
external radiation therapy.  Although additional exter-
nal radiation treatments may be considered for lesions 
that show resistance to initial external radiation 
therapy and medication,  additional radiation is still 
controversial in Japan,  and its indication is generally 
limited.  No eﬀective therapies have been proven as 
safe and eﬀective after failure of such standard thera-
pies in Japan.
　 Cryoablation is a local treatment that induces 
coagulating necrosis by using rapid freezing,  slow 
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thawing,  and repetition of the freeze-thaw cycle ［4］.  
Clinically,  this therapy has already been used for 
various organ tumors,  including those of the kidney 
［5,  6］,  liver ［7］,  lung ［8］ and other organs.  However,  
in Japan,  cryoablation is only covered by national 
health insurance to treat small renal cancers.  Many 
reports show favorable outcomes of cryoablation 
for patients with small renal cell carcinoma ［5,  6］.  
Cryoablation can be performed safely and accurately 
under imaging guidance,  such as computed tomogra-
phy (CT) and magnetic resonance imaging (MRI).  
Additionally,  it can be performed percutaneously with 
minimal invasiveness under local anesthesia and con-
scious sedation.  Therefore,  even if patients cannot 
undergo surgery because of severe comorbidities,  they 
can often be candidates for this therapy.
　 Recently,  percutaneous radiofrequency (RF) abla-
tion was utilized as eﬀective local therapy for bone 
metastases.  Several investigators reported that 
patient pain was signiﬁcantly improved after this 
therapy ［9］.  Both RF ablation and cryoablation are 
local thermal therapies that require probe insertion 
into the target area under image guidance.  In RF 
ablation,  the ablation zone is usually invisible on CT 
images while performing treatment.  Conversely,  in 
cryoablation,  the ablation zone is visible as an “ice 
ball” during ablation.  Intraprocedural CT images show 
the ice ball as a low attenuation area with sharply 
deﬁned borders ［10］.  Intraprocedural MRI shows the 
ice ball as a markedly hypointense area relative to the 
renal parenchyma ［10］.  Therefore,  cryoablation is 
advantageous in terms of safety and targeting accu-
racy.  Additionally,  measuring the temperature of 
adjacent critical organs and structures at risk of 
thermal injury can increase the safety of this therapy.
　 In general,  conventional external radiation therapy 
requires approximately 2–3 weeks for completion of 
treatment,  and patients experience pain relief gradu-
ally.  If pain recurrence unfortunately occurs after 
radiation therapy,  additional radiation treatments to 
the same area are not always performed because of the 
increased risk of radiation damage.  Conversely,  cryo-
ablation can relieve pain immediately after the proce-
dure ［11］ and can be performed repeatedly even if 
recurrence occurs.  In this regard,  we assumed that 
cryoablation has potential advantages over external 
radiation therapy.  Therefore,  we wanted to evaluate 
the safety of the cryoablation prospectively for 
patients with painful bone and soft tissue tumors.
　 We plan to conduct an exploratory clinical trial to 
evaluate the safety of percutaneous cryoablation treat-
ment of painful soft tissue and bone tumors.  Herein,  
we describe the detailed protocol of this prospective 
feasibility study.
Endpoints
　 Purpose. This study is being conducted to 
evaluate the safety of percutaneous cryoablation,  in 
terms of severe adverse event (SAE) prevalence 4 
weeks after treatment in patients with painful bone and 
soft tissue tumors at our institution.
　 Study design. This study is a single-center,  
single-arm,  prospective,  open-label feasibility study.  
No hypothesis testing is being performed for the pri-
mary endpoint.
　 This study protocol has been approved by the eth-
ics committee of the Okayama University Graduate 
School of Medicine,  Dentistry and Pharmaceutical 
Sciences at Okayama University Hospital (approval 
number,  RIN1511-004).  This study has been regis-
tered with the University Hospital Medical 
Information Network (UMIN) in Japan (trial registra-
tion number: UMIN000019077).
　 Endpoints. The primary endpoint is SAE 
prevalence 4 weeks after undergoing cryoablation.  A 
SAE is an adverse event (AE) that is a signiﬁcant 
hazard or side eﬀect that occurs during this period 
regardless of the investigatorʼs opinion on the relation-
ship between the occurrence and cryoablation.  This 
includes,  but may not be limited to,  any event that is 
fatal,  is life-threatening,  requires or prolongs inpa-
tient hospitalization,  persists or signiﬁcantly disables 
or incapacitates,  or is considered an important medi-
cal event.  Evaluations for AEs after the procedure 
are classiﬁed based on the Common Terminology 
Criteria for Adverse Events (CTCAE) ver.4.0.
　 The secondary endpoints are (1) eﬀectiveness,  as 
measured by relief of the pre-treatment symptoms and 
changes between pre- and postoperative radiological 
images of the target lesions,  (2) procedure- or device-
related AEs,  and (3) device malfunction.  Each sec-
ondary endpoint will be evaluated 4 weeks after the 
procedure.
　 Local pain related to the target lesion will be 
evaluated by using the visual analogue scale.  
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Subsequently,  the prevalences of symptom-free,  
improved,  stable,  or progressing disease,  which will 
be evaluated using pretreatment scores,  will be calcu-
lated.  To evaluate vascularity and target lesion size,  
contrast-enhanced CT or MRI images will be obtained 
before and 4 weeks after the procedure.
　 Procedure-related AEs are deﬁned as any new,  
undesirable medical occurrences or worsening of a pre-
existing condition that occur in a subject and are con-
sidered to be associated with the procedure.  Device-
related AEs are deﬁned as any new,  undesirable 
medical occurrences or changes considered to be 
associated with cryoablation products.
Eligibility Criteria
　 Inclusion criteria. 1) The patient has painful 
bone and soft tissue tumors that are resistant to 
medication.  2) The target lesion is histopathologically 
diagnosed.  3) The target lesion can be evaluated with 
imaging,  i.e.,  CT and/or MRI,  before and after cryo-
ablation.  4) The patient is expected to survive more 
than 1 month after registration for this study.  5) 
Written informed consent for percutaneous cryoabla-
tion is obtained from the patient.  6) The patient is 
equal to or more than 20 years old.  7) The patient is 
not a candidate for or refuses to undergo surgical 
resection for the target lesion.
　 Exclusion criteria. 1) Cryoprobe insertion 
cannot be performed safely because of vital organs 
and/or vessels on the insertion route.  2) The patient 
has heart failure (New York Heart Association 
Functional Classiﬁcation Ⅲ) and/or active infection,  
with the exception of viral hepatitis.  3) The patient 
has a body temperature of 38℃ or more.  4) The tar-
get lesion cannot be evaluated with imaging,  i.e.,  CT 
and/or MRI.  5) The patient is conﬁrmed or suspected 
of being pregnant.  6) The patient is at risk of worsen-
ing pathological fracture due to cryoablation.  7) The 
patient is at risk of worsening QOL due to cryoabla-
tion.  8) Main organ functions are abnormal based on 
the blood and biochemical tests as follows: i) white 
blood cell count ＜2,500/µL; ii) platelet count ＜
50,000/µL; iii) hemoglobin＜6.0g/dL; iv) creatinine 
＞2.0mg/dL; or v) total bilirubin＞3.0mg/dL.  9) 
The patient is regarded as inappropriate for this study 
by physicians.
Treatment Methods
　 Cryoablation procedure. In this study,  cryo-
ablation for bone and soft tissue tumors will be per-
formed under ultrasound,  CT,  or MRI guidance.  
Under local anesthesia,  one or more cryoprobes 
(IceRod or IceSeed,  Galil Medical,  Yokneam,  Israel) 
will be introduced into the target lesions percutane-
ously.  Each cryoprobe will be connected to an argon-
based cryoablation system (CryoHit,  Galil Medical).  
The standard ablation protocol includes a double 
freeze cycle in 2 cycles of maximum 15-min freezes 
separated by 2 min of thawing.  As the ablated zone is 
visible as an ice ball,  the ablation procedure generally 
aims to cover the target lesion and 6-mm ablative 
margins,  creating the ice ball.  However,  to ensure 
safety,  the aforementioned ablation protocol may be 
altered.  For lesions located adjacent to the skin or 
visible nerves,  for example,  freezing duration is 
decreased in order to limit ice ball size and avoid 
injury to the skin or nerves.  After ablation,  cryo-
probes are withdrawn,  and CT or MRI images of the 
ablated target lesion are obtained to evaluate proce-
dure- or device-related AEs (e.g.,  hematoma or adja-
cent organ injury).  Characteristics of target lesions,  
ablation protocols for each patient,  and AEs after the 
procedure will be recorded on case report forms.
　 Temperature measurement. In this study,  
the operator will insert the temperature sensor 
(Fluoroptic Temperature Probe; LumaSense 
Technologies,  CA,  USA) near adjacent critical 
organs and structures during the procedure to deter-
mine potential risk of thermal injury caused by cryo-
ablation on pre-ablative images.  First,  an 18-gauge 
coaxial needle (Surﬂo; Terumo,  Tokyo,  Japan) or a 
20-gauge coaxial catheter for percutaneous transhe-
patic biliary drainage (Happycath; Medikit,  Tokyo,  
Japan) will be inserted near the surface of the adjacent 
organs/structures under CT guidance.  The internal 
needle will be withdrawn,  and subsequently,  the 
temperature sensor will be advanced into the outer 
catheter to the surface of the adjacent organs/struc-
tures.  During cryoablation,  the temperature will be 
continuously measured and recorded.  If the operator 
determines that there may be a high risk of thermal 
injury for adjacent organs/structures,  the cryoabla-
tion procedure will temporarily be discontinued,  and 
the position of cryoprobes will be changed as needed.
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Statistical Consideration
　 Statistical analysis. Clinical data obtained in 
this study will be summarized using descriptive statis-
tics.  The results of all endpoint analyses are reported 
as the proportion of cases and the 95  conﬁdence 
interval,  which is presented as Agresti and Coull 
upper and lower limits.
　 Interim analysis and monitoring. An interim 
analysis is not planned during the study period.  The 
data and safety monitoring committee (DSMC) inde-
pendently reviews the report of SAEs,  if present,  
and decides to terminate studies early.  In-house moni-
toring will be performed to ensure patient eligibility,  
protocol compliance,  data submission,  and proper 
reporting of AEs related to the cryoablation.  The 
monitoring reports will be submitted to and reviewed 
by the independent DSMC.
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